Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Nutrition 21, LLC Announces The Presentation Of Results Of A Nitrosigine™ Clinical Study At The Renowned Experimental Biology 2014 Annual Meeting
  • USA - English


News provided by

Nutrition 21

May 05, 2014, 09:45 ET

Share this article

Share toX

Share this article

Share toX

NO was measured using salivary test strips in a 10 subject clinical study, using a color scale for “Depleted”, “Low”, and “Normal” levels.
NO was measured using salivary test strips in a 10 subject clinical study, using a color scale for “Depleted”, “Low”, and “Normal” levels.

Purchase, NY (PRWEB) May 05, 2014 -- Nutrition 21, LLC (“Nutrition 21”) is proud to announce the presentation of a new clinical study supporting Nitrosigine™ inositol-stabilized arginine silicate, titled, “A Clinical Evaluation to Determine the Safety, Pharmacokinetics and Pharmacodynamics of an Inositol-Stabilized Arginine Silicate Dietary Supplement in Healthy Adult Males.” The study will be presented today to scientists and other professionals at the acclaimed Experimental Biology 2014 annual meeting’s poster session and will be published in the FASEB (Federation of American Societies for Experimental Biology) Journal.

The clinical study demonstrated significant increases in plasma arginine levels (P<0.01) and serum silicon levels (P<0.01) after a single dose of Nitrosigine™. In addition, a significant increase in nitric oxide levels (measured as salivary nitrites) was seen after 14 days of product consumption (P<0.05). The results of the clinical study support the use of Nitrosigine™ as a bioavailable source of arginine and silicon, validating the preclinical studies and confirming Nitrosigine™ as an effective ingredient in products for sports nutrition, men’s health and cardiovascular health.

The clinical study verified Nitrosigine™ supplementation increased nitric oxide (NO) levels with a significant change in NO levels between the first treatment visit and after 14 days. The increase in NO levels can promote relaxation of smooth muscle in blood vessels, which increases blood flow and improves cardiovascular and muscular health.

Primary author, Douglas S. Kalman, PhD, RD, CCRC, FACN, Director BD, Nutrition & Applied Clinical Trials at Miami Research Associates stated, “Nitrosigine, a new FDA-approved arginine-based molecule, has early and preliminary research that is deserving of further development.”

Michael Satow, President and Chief Executive Officer of Nutrition 21 commented, “We are immensely pleased with the new clinical results, confirming our pre-clinical studies, and furthermore supporting Nitrosigine™’s ability to significantly increase nitric oxide levels to optimize the benefits of rigorous workouts. Fitness-focused customers who want to get the most out of their training regimen, will appreciate that Nitrosigine™ is quickly absorbed by the body, taking effect in 30 minutes and lasting up to three hours. Nitrosigine™ has also been shown to significantly raise arginine and silicon levels - both important nutrients for cardiovascular performance.”

Consumer benefits directly linked to the study findings include:
• Nitrosigine™ significantly enhances nitric oxide levels
• Nitrosigine™ is a safe, bioavailable source of arginine and silicon
• Nitrosigine™ significantly increases plasma arginine levels in 30 minutes
• Nitrosigine™ significantly increases plasma arginine levels for up to 3 hours
• Nitrosigine™ significantly increases silicon levels for up to 1.5 hours

“Nutrition 21 is thrilled to have the human clinical study available as support for our NDI accepted, Nitrosigine™. Based on clinical and pre-clinical results, Nitrosigine™ demonstrates superiority over arginine as shown by increases in blood flow markers and silicon absorption. Nitrosigine™ is currently available in the retail channel in products such as, SuperPump® 3.0 and Razor8® and is in development in other finished goods. We anticipate continued high market interest with robust customer sales,” said Jim Kahn, Executive Director of National Sales at Nutrition 21.

About Experimental Biology 2014

The Experimental Biology (EB) meeting is a multi-society, interdisciplinary, biomedical, scientific meeting featuring plenary and award lectures, symposia, oral and poster sessions, a placement center, and an exhibit of scientific equipment, supplies, and publications. The meeting is one of the largest to date with over 14,000 attending scientists and researchers in the fields of anatomy, physiology, biochemistry, pathology, nutrition, and pharmacology. The Experimental Biology (EB) 2014 meeting will be held at the San Diego Convention Center, April 26 - 30, 2014.

For more information about the Experimental Biology 2014 annual meeting, please visit: http://www.experimentalbiology.org

About the Federation of American Societies for Experimental Biology (FASEB) Journal

The FASEB Journal is one of the world's most cited biology journals. It is a preferred venue for the latest research reports and reviews of epigenetics, iRNA mechanics, histone acetylation, nitric oxide signaling, eicosanoid biochemistry, angiogenesis, tumor suppressor genes, apoptosis, cytoskeletal function, and human stem cell research. The journal publishes peer-reviewed, multidisciplinary original research articles, as well as editorials, reviews, and news of the life sciences.

For more information about the Federation of American Societies for Experimental Biology, please visit: http://www.FASEB.org

About Nutrition 21, LLC

Nutrition 21, a wholly owned subsidiary of JDS Therapeutics, is a leader in the nutritional supplement industry. The Company is a developer and marketer of efficacious, high-value, clinically substantiated ingredients for dietary supplements, medical foods and beverages, including CHROMAX® chromium picolinate and NITROSIGINE™ inositol-stabilized arginine silicate. In 2013 NITROSIGINE™ was accepted by the FDA as a New Dietary Ingredient (NDI).

With many years of biotechnology and pharmaceutical experience, the Company’s scientific platform has created unique, patentable products that are safe and clinically effective. Rigorous preclinical and clinical trials are a key part of its product development strategy to ensure product safety and consumer trust.

Nutrition 21 currently holds over 100 domestic and international issued and pending patents for products. Many support unique claims associated with, among others, glucose metabolism, weight management, brain health, cardiovascular health, and sports nutrition.

For more information, please visit: http://www.Nutrition21.com

Bill Levi, Nutrition 21, http://www.nutrition21.com/, +1 (914) 701-4549, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.